Top

Open Access 26-03-2024 | Parathyroidectomy | Original Article

Changes in cardiac functions in patients treated with parathyroidectomy for secondary hyperparathyroidism

Authors: Sami Benli, Emrah Yesil, Deniz Tazeoglu, Cumhur Ozcan, Ismail Turkay Ozcan, Ahmet Dag

Abstract

Our study aims to investigate the changes in cardiac functions, especially myocardial performance index (MPI), in patients who underwent parathyroidectomy for secondary hyperparathyroidism. Patients who underwent parathyroidectomy for secondary hyperparathyroidism between June 2010 and September 2021 were analyzed retrospectively. The patients were divided into two groups: those who underwent total parathyroidectomy (group 1) and those who underwent subtotal parathyroidectomy (group 2). The groups were compared according to the echocardiogram findings performed in the preoperative period and the postoperative sixth month. In addition, cardiac structure, and systolic and diastolic functions, especially myocardial performance index, were evaluated by echocardiography and Doppler imaging. Thirty-seven patients were examined; 16 (43.2%) underwent total parathyroidectomy, and 21 (56.8%) had subtotal parathyroidectomy performed. Group 1’s mean left ventricular end-systolic diameter (LVES) decreased from 2.53 ± 0.57 to 2.35 ± 0.37 cm after parathyroidectomy. In Group 1, the postoperative value of LVES and end-systolic volume decreased significantly compared to the preoperative period (p = 0.042, p = 0.008, respectively). EF increased from 59.25 ± 0.05 to 67.81 ± 4.04. In Group 1, EF and EV postoperatively increased significantly compared to the preoperative period (p = 0.023, p = 0.021, respectively). The mean MPI decreased from 0.45 ± 0.07 to 0.39 ± 0.04 after parathyroidectomy in group 1. In group 2, it decreased from 0.46 ± 0.06 to 0.40 ± 0.04 (p < 0.001). The present study provides an improvement in myocardial functions after parathyroidectomy. While LVES, EF, ejection volume, end-systolic volume, and MPI improved in both groups, the MPI improvement was more evident in the total parathyroidectomy group.

Graphical Abstract

Rodríguez-Ortiz ME, Rodríguez M (2020) Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Res 9:F1000 Faculty Rev-1077. https://doi.org/10.12688/f1000research.22636.1

van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S (2020) Secondary and tertiary hyperparathyroidism: a narrative review. Scand J Surg 109(4):271–278. https://doi.org/10.1177/1457496919866015CrossRefPubMed

Isakova T, Nickolas TL, Denburg M et al (2017) KDOQI US Commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 70(6):737–751. https://doi.org/10.1053/j.ajkd.2017.07.019CrossRefPubMed

Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12(10):2131–2138. https://doi.org/10.1681/ASN.V12102131CrossRefPubMed

Moe SM, Chertow GM, Coburn JW et al (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67(2):760–771. https://doi.org/10.1111/j.1523-1755.2005.67139.xCrossRefPubMed

Rodríguez-Ortiz ME, Pendón-Ruiz de Mier MV, Rodríguez M (2019) Parathyroidectomy in dialysis patients: indications, methods, and consequences. Semin Dial. 32(5):444–451. https://doi.org/10.1111/sdi.12772CrossRefPubMed

van der Plas WY, Dulfer RR, Koh EY et al (2018) Safety and efficacy of subtotal or total parathyroidectomy for patients with secondary or tertiary hyperparathyroidism in four academic centers in the Netherlands. Langenbecks Arch Surg 403(8):999–1005. https://doi.org/10.1007/s00423-018-1726-6CrossRefPubMedPubMedCentral

Zhang Y, Lu Y, Feng S, Zhan Z, Shen H (2019) Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Ren Fail 41(1):921–929. https://doi.org/10.1080/0886022X.2019.1666724CrossRefPubMedPubMedCentral

Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y (2005) Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 20(8):1714–1720. https://doi.org/10.1093/ndt/gfh892CrossRefPubMed

10.

Chow KM, Szeto CC, Kum LC et al (2003) Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. J Nephrol 16(6):878–885PubMed

11.

Takahashi H, Komaba H, Takahashi Y et al (2014) Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. J Clin Endocrinol Metab 99(4):E652–E658. https://doi.org/10.1210/jc.2013-4050CrossRefPubMed

12.

Lax JA, Bermann AM, Cianciulli TF, Morita LA, Masoli O, Prezioso HA (2000) Estimation of the ejection fraction in patients with myocardial infarction obtained from the combined index of systolic and diastolic left ventricular function: a new method. J Am Soc Echocardiogr 13(2):116–123. https://doi.org/10.1016/s0894-7317(00)90022-1CrossRefPubMed

13.

Mikkelsen KV, Møller JE, Bie P, Ryde H, Videbaek L, Haghfelt T (2006) Tei index and neurohormonal activation in patients with incident heart failure: serial changes and prognostic value. Eur J Heart Fail 8(6):599–608. https://doi.org/10.1016/j.ejheart.2005.11.015CrossRefPubMed

14.

Nanasato M, Goto N, Isobe S et al (2009) Restored cardiac conditions and left ventricular function after parathyroidectomy in a hemodialysis patient. Parathyroidectomy improves cardiac fatty acid metabolism assessed by 123I-BMIPP. Circ J. 73(10):1956–1960. https://doi.org/10.1253/circj.cj-08-0415CrossRefPubMed

15.

Tei C, Ling LH (1995) New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 26:357–366PubMed

16.

Kjaergaard J, Hassager C, Oh JK, Kristensen JH, Berning J, Sogaard P (2005) Measurement of cardiac time intervals by Doppler tissue M-mode imaging of the anterior mitral leaflet. J Am Soc Echocardiogr 18:1058–1065CrossRefPubMed

17.

Lau WL, Obi Y, Kalantar-Zadeh K (2018) Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol 13(6):952–961. https://doi.org/10.2215/CJN.10390917CrossRefPubMedPubMedCentral

18.

Hiramitsu T, Hasegawa Y, Futamura K et al (2023) Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol 14:1169793. https://doi.org/10.3389/fendo.2023.1169793CrossRef

19.

McCullough PA, Sandberg KR, Dumler F, Yanez JE (2004) Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 17(2):205–215PubMed

20.

Sigrist MK, Taal MW, Bungay P, McIntyre CW (2007) Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2(6):1241–1248. https://doi.org/10.2215/CJN.02190507CrossRefPubMed

21.

Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A (2004) Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15(3):770–779. https://doi.org/10.1097/01.asn.0000113243.24155.2fCrossRefPubMed

22.

Daniel WT, Weber C, Bailey JA, Raggi P, Sharma J (2013) Prospective analysis of coronary calcium in patients on dialysis undergoing a near-total parathyroidectomy. Surgery 154(6):1315–1322. https://doi.org/10.1016/j.surg.2013.06.030CrossRefPubMed

23.

Vogt I, Haffner D, Leifheit-Nestler M (2019) FGF23 and phosphate-cardiovascular toxins in CKD. Toxins 11(11):647. https://doi.org/10.3390/toxins11110647CrossRefPubMedPubMedCentral

24.

Rodelo-Haad C, Santamaria R, Muñoz-Castañeda JR, Pendón-Ruiz de Mier MV, Martin-Malo A, Rodriguez M (2019) FGF23, biomarker or target? Toxins 11(3):175. https://doi.org/10.3390/toxins11030175CrossRefPubMedPubMedCentral

25.

Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G (2005) Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 46(2):320–327. https://doi.org/10.1053/j.ajkd.2005.04.031CrossRefPubMed

26.

Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393–4408. https://doi.org/10.1172/JCI46122CrossRefPubMedPubMedCentral

27.

Di Marco GS, Reuter S, Kentrup D et al (2014) Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant 29(11):2028–2035. https://doi.org/10.1093/ndt/gfu190CrossRefPubMedPubMedCentral

28.

Molkentin JD (2004) Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63(3):467–475. https://doi.org/10.1016/j.cardiores.2004.01.021CrossRefPubMed

29.

Menon V, Greene T, Pereira AA et al (2005) Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 46(3):455–463. https://doi.org/10.1053/j.ajkd.2005.05.025CrossRefPubMed

30.

Chen S, Sheng K, Shen Y et al (2020) Impact of parathyroidectomy on left ventricular function in end stage renal disease patients. BMC Nephrol 21(1):479. https://doi.org/10.1186/s12882-020-02139-3CrossRefPubMedPubMedCentral

31.

Goto N, Tominaga Y, Matsuoka S et al (2005) Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol 9(2):138–141. https://doi.org/10.1007/s10157-005-0351-1CrossRefPubMed

32.

van Ballegooijen AJ, Visser M, Cotch MF et al (2013) Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab 98(6):2544–2552. https://doi.org/10.1210/jc.2012-4252CrossRefPubMedPubMedCentral

33.

LaCorte JC, Cabreriza SE, Rabkin DG et al (2003) Correlation of the Tei index with invasive measurements of ventricular function in a porcine model. J Am Soc Echocardiogr 16(5):442–447. https://doi.org/10.1016/s0894-7317(03)00110-xCrossRefPubMed

34.

Mansour H, Nassar AI, Abdel Rehim WA et al (2021) Can Tei index predict high syntax score in patients with chronic coronary syndrome and normal left ventricular systolic function? J Cardiovasc Echogr 31(1):11–16. https://doi.org/10.4103/jcecho.jcecho_73_20CrossRefPubMedPubMedCentral

Title: Changes in cardiac functions in patients treated with parathyroidectomy for secondary hyperparathyroidism
Authors: Sami Benli
Emrah Yesil
Deniz Tazeoglu
Cumhur Ozcan
Ismail Turkay Ozcan
Ahmet Dag
Publication date: 26-03-2024
Publisher: Springer International Publishing
Keywords: Parathyroidectomy
Parathyroidectomy
Hyperparathyroidism
Echocardiography
Echocardiography
Published in: Updates in Surgery
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-024-01812-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in cardiac functions in patients treated with parathyroidectomy for secondary hyperparathyroidism

Abstract

Graphical Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content